Background:
Pericarditis, inflammation of the pericardium, is the most prevalent
pericardial disease and a prominent cause of acute chest discomfort in
young people (1). It is mostly caused by viral infections as well as
rheumatic illnesses, uremia, or neoplasms (2). A pericardial friction
rub, concave ST-segment elevations, pleuritic chest discomfort, and
pericardial effusion are all common indications and symptoms (1). Given
that pericarditis is generally self-limited, the therapy is usually
supportive, including nonsteroidal anti-inflammatory medications or
colchicine. Other causes of pericarditis, on the other hand, may have
different prognosis and therapeutic implications (3, 4).
Up to 15% over all acute myocardial infarction (AMI) patients and 25%
of individuals with anterior myocardial infarction suffer from a left
ventricular thrombus (LVT) (5, 6). With the introduction of early
percutaneous coronary intervention (PCI) as a widely used treatment of
AMI, the incidence of LVT decreased dramatically. LVT is most typically
seen in patients with late-onset MI in clinical practice. It is
infrequently seen in patients who report early and receive fast
revascularization, especially in the first 24 hours after an AMI (7).
Coronavirus Disease 2019 (COVID-19) has grown significantly in scale as
a result of the development of the novel Zoonotic Severe Acute
Respiratory Syndrome Coronavirus-2. In addition to the predominance of
respiratory symptoms, cardiovascular problems have also been
reported(8).
A COVID-19 patient with ST elevation MI and LV thrombus with signs and
symptoms of pericarditis was introduced.